Five NHS specialist centres manage more than 90% of UK HAE patients, evidence of how concentrated UK HAE expertise for this disease actually is.
UK HAE expertise concentrates around a small number of NHS specialist centres, not a broad national field. Sheffield, Cambridge, Birmingham, Guy's and St Thomas', and Manchester together manage more than 90% of the UK's estimated 5,000 to 6,000 HAE patients, a specialist network entrenched by NICE TA606 lanadelumab commissioning since 2019. That kind of concentrated referral structure does not happen without an established national collaboration network, coordinated through the UK HAE Alliance patient-advocacy body. Our KOL Universe gate (K1) starts by mapping exactly this kind of institutional concentration before any single physician is scored.
That structure changes how AXLRx tiers influence in the UK. A specialist working within one of the five entrenched centres carries different scientific weight than one operating outside that network, and our Tier Classification gate (K2) scores that distinction directly, alongside guideline-committee roles at BSACI (British Society for Allergy and Clinical Immunology) and NICE technology-appraisal engagement history. No named individual enters the workbook without a verification tag; every KOL identity is checked against live publication records and institutional affiliations, then marked Verified, Industry benchmark, or Requires client validation. A commercial team engaging the wrong tier wastes MSL capacity on a specialist with no real influence over prescribing peers, which is exactly what the K1-K6 gate structure is built to prevent.
The UK HAE specialist network — five NHS centres, more than 90% of patients
| Centre | City | Role in Network |
|---|---|---|
| Sheffield HAE specialist centre | Sheffield | NHS specialist HAE service |
| Cambridge HAE specialist centre | Cambridge | NHS specialist HAE service |
| Birmingham HAE specialist centre | Birmingham | NHS specialist HAE service |
| Guy's and St Thomas' HAE specialist centre | London | NHS specialist HAE service |
| Manchester HAE specialist centre | Manchester | NHS specialist HAE service |
Sources: AXLRx UK Hereditary Angioedema Launch-Readiness assessment; NICE TA606 commissioning documentation (published 16 October 2019); UK HAE Alliance annual report 2023.
What this workbook answers
Every section answers a named commercial question your team is asking, scoped to your asset.
Delivers
- The five-centre NHS network structure (Sheffield, Cambridge, Birmingham, Guy's and St Thomas', Manchester)
- institutional concentration as a KOL-tiering signal
- K1 KOL Universe Sizing methodology
Delivers
- K2 Tier Classification methodology
- BSACI guideline-committee weighting and NICE TA-submission history
- K3 Scientific Influence scoring inputs
Delivers
- The three-tag verification protocol (Verified/Industry benchmark/Requires client validation)
- live publication and institutional-affiliation cross-checks
- why no placeholder name ships unflagged
Custom workbook delivered in 72 hours.
Commission This WorkbookWhat's inside
- Why institutional concentration, not scattergun individual outreach, is the single variable this workbook sizes first
- Pressure-tested against the five-centre NHS network before the rest of the workbook is built out
- Every UK HAE KOL sized and sourced from publication and institutional-affiliation data
- The five-centre NHS network as the sizing anchor
- Universe boundaries: who counts as a KOL versus a high-volume prescriber
- Scientific-influence scoring across NICE technology-appraisal engagement and BSACI guideline-committee membership
- What separates a Tier 1 KOL from a high-volume community prescriber
- Influence inputs: NICE TA submission authorship, guideline-committee role, centre leadership
- Cross-checked against independent publication and citation data
- Readiness scoring and channel recommendations per KOL
- Sequencing implications for MSL deployment
- Territory-to-KOL coverage map across Sheffield, Cambridge, Birmingham, London, and Manchester
- Where current MSL deployment has gaps
- Multi-market reach for KOLs active beyond the NHS, across EU5 and wider Europe
- Implications for coordinated versus purely local engagement
- The open KOL-engagement questions your medical affairs team must close
- Structured for an internal alignment session before MSL deployment
Included with every brief
How AXLRx builds this workbook
Prepared by MoatRx analysts.
Every AXLRx KOL workbook is built from live publication records and institutional-affiliation data, not secondary summaries. No KOL name ships without a verification tag.
UK HAE KOL sources: the five-centre NHS specialist network (Sheffield, Cambridge, Birmingham, Guy's and St Thomas', Manchester) entrenched by NICE TA606 lanadelumab commissioning; the UK HAE Alliance annual report 2023; and BSACI guideline-committee membership records.
- Five-centre NHS specialist network and the greater-than-90% patient-share figure verified against NICE TA606 commissioning documentation and the UK HAE Alliance annual report 2023
- Prophylaxis-eligible but never-treated patient range (1,500-2,500) verified against the AXLRx UK Hereditary Angioedema Launch-Readiness assessment
- Every KOL entry in the underlying workbook carries a three-tag verification status before delivery: Verified, Industry benchmark, or Requires client validation
Frequently asked questions
Commission this workbook
AXLRx delivers KOL mapping workbooks built for medical affairs and commercial teams engaging UK hereditary angioedema specialists. Custom workbook in 72 hours.
Specify your indication, geography, and centre scope.
AXLRx analyst confirms centre scope and verification standard before building.
Research-verified KOL workbook in 72 hours with optional analyst readout.